Inert benzothiazole functionalised ruthenium(ii) complexes; potential DNA hairpin binding agents

Noni (Morinda Citrifolia) is a herb which has effect to cure cancer, high blood pressure, etc. Makes the smell and the taste of noni less delicious because there are a number of organic acid like caproic acid and caprilic acid in noni. Therefore it needs an alternative product such as pressed candy. Correct process of extraction and addition of binding agents can produce the pressed candy with the physical, chemical and organoleptic characteristic that are expected. The objective of this research wash to know the optimum ratio of noni compared with ethanol so it can produce dry extrac of noni fruit with vitamin C and high activity antioxidant and also to know the influence of binding agents type in the making of noni pressed candy. This research use the Randomized Block Design (RBD), where at antecedent research consisted of 3 (three) levels which is ratio of noni fruit compared by ethanol (1:1, 1:2, 1:3) and best treatment used for the main research. Main research consisted of 3 (three) levels that was influence of binding agents type (maltodextrin 5%, gelatin 1,5% and gom arab 1%). Then its continued with the BNT test at ? = 0,05 (differing reality). Test of organoleptic done by hedonic score test. Best treatment uses multiple attribute method. The result of research show that the best treatment from dry filtrate of noni fruit was with the ratio of noni fruit compared by ethanol = 1:3. Best treatment of noni fruit pressed candy is with the gelatin addition 1,5 %.

Faculty Opinions recommendation of Total synthesis of proximicin A-C and synthesis of new furan-based DNA binding agents.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166298.627246 ◽

2009 ◽

Author(s):

Robert Fecik

Keyword(s):

Dna Binding ◽

Total Synthesis ◽

Binding Agents ◽

Dna Binding Agents

Carbohydrate-Binding Agents: Potential of Repurposing for COVID-19 Therapy

Current Protein and Peptide Science ◽

10.2174/1389203721666200918153717 ◽

2020 ◽

Vol 21 (11) ◽

pp. 1085-1096 ◽

Cited By ~ 2

Author(s):

Rajesh Kumar Gupta ◽

Girish R. Apte ◽

Kiran Bharat Lokhande ◽

Satyendra Mishra ◽

Jayanta K. Pal

Keyword(s):

Vaccine Development ◽

Host Cells ◽

Carbohydrate Binding ◽

Atypical Pneumonia ◽

The Novel ◽

High Infection ◽

Binding Agents ◽

Current Scenario ◽

Antiviral Activities ◽

Novel Drug

: With the emergence of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the whole world is suffering from atypical pneumonia, which resulted in more than 559,047 deaths worldwide. In this time of crisis and urgency, the only hope comes from new candidate vaccines and potential antivirals. However, formulating new vaccines and synthesizing new antivirals are a laborious task. Therefore, considering the high infection rate and mortality due to COVID-19, utilization of previous information, and repurposing of existing drugs against valid viral targets have emerged as a novel drug discovery approach in this challenging time. The transmembrane spike (S) glycoprotein of coronaviruses (CoVs), which facilitates the virus’s entry into the host cells, exists in a homotrimeric form and is covered with N-linked glycans. S glycoprotein is known as the main target of antibodies having neutralizing potency and is also considered as an attractive target for therapeutic or vaccine development. Similarly, targeting of N-linked glycans of S glycoprotein envelope of CoV via carbohydrate-binding agents (CBAs) could serve as an attractive therapeutic approach for developing novel antivirals. CBAs from natural sources like lectins from plants, marine algae and prokaryotes and lectin mimics like Pradimicin-A (PRM-A) have shown antiviral activities against CoV and other enveloped viruses. However, the potential use of CBAs specifically lectins was limited due to unfavorable responses like immunogenicity, mitogenicity, hemagglutination, inflammatory activity, cellular toxicity, etc. Here, we reviewed the current scenario of CBAs as antivirals against CoVs, presented strategies to improve the efficacy of CBAs against CoVs; and studied the molecular interactions between CBAs (lectins and PRM-A) with Man9 by molecular docking for potential repurposing against CoVs in general, and SARSCoV- 2, in particular.

Binding Agents Offer Strategy for Blocking Botulinum, Other Toxins

Microbe Magazine ◽

10.1128/microbe.5.234.1 ◽

2010 ◽

Vol 5 (6) ◽

pp. 234-234

Author(s):

Carol Potera

Keyword(s):

Binding Agents

ACTIVATION OF PHOSPHOGLUCOMUTASE BY METAL-BINDING AGENTS

Journal of Biological Chemistry ◽

10.1016/s0021-9258(19)51241-8 ◽

1949 ◽

Vol 180 (3) ◽

pp. 1279-1284 ◽

Cited By ~ 1

Author(s):

Earl W. Sutherland

Keyword(s):

Metal Binding ◽

Binding Agents

Microtubule-binding agents: a dynamic field of cancer therapeutics

Nature Reviews Drug Discovery ◽

10.1038/nrd3253 ◽

2010 ◽

Vol 9 (10) ◽

pp. 790-803 ◽

Cited By ~ 969

Author(s):

Charles Dumontet ◽

Mary Ann Jordan

Keyword(s):

Cancer Therapeutics ◽

Microtubule Binding ◽

Dynamic Field ◽

Binding Agents

Binding mode and affinity studies of DNA-binding agents using topoisomerase I DNA unwinding assay

Bioorganic & Medicinal Chemistry Letters ◽

10.1016/j.bmcl.2006.11.038 ◽

2007 ◽

Vol 17 (4) ◽

pp. 1013-1017 ◽

Cited By ~ 22

Author(s):

Ruel E. McKnight ◽

Aaron B. Gleason ◽

James A. Keyes ◽

Sadia Sahabi

Keyword(s):

Dna Binding ◽

Topoisomerase I ◽

Binding Mode ◽

Dna Unwinding ◽

Binding Agents ◽

Dna Binding Agents